Innoviva (INVA) Cash & Equivalents Growth (1y) (2011 - 2026)
Powered by 
Analysis
Innoviva (INVA) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 28.50% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -57.58% |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 43.48% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 43.48% |
| Mar 31, 2026 | 89.00% |
| Dec 31, 2025 | 80.66% |
| Sep 30, 2025 | 82.83% |
| Jun 30, 2025 | 83.19% |
| Mar 31, 2025 | 78.91% |
| Dec 31, 2024 | 57.59% |
| Sep 30, 2024 | 44.80% |
| Jun 30, 2024 | 25.42% |
| Mar 31, 2024 | 23.82% |
| Dec 31, 2023 | -33.51% |
| Sep 30, 2023 | -40.16% |
| Jun 30, 2023 | -38.99% |
| Mar 31, 2023 | -33.56% |
| Dec 31, 2022 | 44.42% |
| Sep 30, 2022 | 122.62% |
| Jun 30, 2022 | 555.45% |
| Mar 31, 2022 | -23.36% |
| Dec 31, 2021 | -18.24% |
| Sep 30, 2021 | -71.80% |